Enanta Pharmaceuticals (ENTA) Fundamentals 2026 — Revenue Analysis | SniperIQ
Enanta Pharmaceuticals (ENTA) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Enanta Pharmaceuticals (ENTA) has a market capitalization of approximately
Enanta Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Enanta Pharmaceuticals runs a net profit margin of -89.6%, a gross margin of 98.3%, and an operating margin of -87.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Enanta Pharmaceuticals reported revenue of $65M for fiscal year 2025, with net income of -$82M and earnings per share (EPS) of -3.84. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Enanta Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Enanta Pharmaceuticals carries a debt-to-equity ratio of 1.60x and a current ratio of 3.84x, with a market beta of 0.97. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Enanta Pharmaceuticals (ENTA) the key facts are: market cap
Get Enanta Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.